Bastos, Victoria C, Greene, Kerrie A, Tabachnikova, Alexandra et al. · Journal of immunology (Baltimore, Md. : 1950) · 2025 · DOI
Quick Summary
Researchers studied cerebrospinal fluid (the fluid around the brain and spinal cord) from people with ME/CFS and found that the immune system appears to work differently in different patients. They discovered two distinct patient groups with different immune patterns and pathogen exposure histories, even though both groups had similar symptoms. This suggests that ME/CFS may not be a single disease, but rather several related conditions with different underlying causes.
Why It Matters
ME/CFS patients have long struggled with the lack of biological diagnostic markers and recognition that different patients may need different treatments. This study provides evidence for biological subtypes within ME/CFS, which could eventually lead to more targeted, effective treatments tailored to individual immune profiles rather than a one-size-fits-all approach.
Observed Findings
Two distinct patient clusters were identified based on cerebrospinal fluid matrix metalloproteinase profiles
The two subgroups had similar clinical symptoms but different pathogen exposure histories
Altered interaction patterns between circulating biological factors were found in ME/CFS plasma compared to healthy controls
The subgroups demonstrated distinct inflammatory profiles in cerebrospinal fluid
Autoantibody profiles and immune markers differed between the identified subgroups
Inferred Conclusions
ME/CFS is likely a heterogeneous disease with multiple distinct pathophysiological mechanisms rather than a single uniform condition
Matrix metalloproteinase profiling may help identify clinically meaningful ME/CFS subtypes
Different patient subgroups may require different diagnostic and therapeutic approaches
Pathogen exposure history may play a role in disease heterogeneity among ME/CFS patients
Remaining Questions
Are these immunotypes stable over time, or do they change as disease progresses?
Do the identified immunotypes predict treatment response or prognosis?
What This Study Does Not Prove
This study does not establish that the identified immunotypes cause ME/CFS symptoms or that they are stable over time—only that they exist at a single time point. It also does not determine whether these immune patterns are unique to ME/CFS or shared with other conditions, and it does not yet predict which treatments would work best for each immunotype.